



MicroPort Scientific Corporation

2022 Annual Results

March 2023

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.

Contents


- 1 **Company Highlights**
- 2 **Business Review**
- 3 **Financial Review**
- 4 **Outlook**
- 5 **Appendix – Financial Statements**





**Building a super-conglomerate of people centric enterprises of
EMERGING MEDICAL TECHNOLOGIES**

2022 Highlights



Newly obtained
registration approvals

25

NMPA²

7

FDA

6



30

NMPA Green
Path products

-No.1 in industry for 8 consecutive years



Business highlights¹



Cardio-vascular

- International revenue **↑60%** YOY, intl. DES revenue **up 63%** YOY
- EMEA **↑143%**, South America **↑59%**, India JV **↑25%**
- Balloon revenue **↑28%** YOY, intl. balloon sales **↑81%** YOY



CRM

- Non-China **3%** YOY (Middle East **↑293%**, Latin America **↑249%**, Australia **↑35%**), soaring sales of Bluetooth® pacemakers
- China **↑7%** YOY, **1st** MRI domestic pacemaker approved & commercialized



Heart valve

- Revenue **↑25%** YOY (**2,625 cases**, **↑~34%**); GPM **+6** ppts (**65%**)
- Overseas sales **↑626%** YOY with **~100** commercial implantations



Electro-physiology³

- Revenue **↑37%** YOY, returning to profit; successfully listed on the **SSE STAR** market
- Multiple products won tenders in Fujian provincial-league VBP, **EasyStars® won exclusive bid** in "singleton-procurement" of high-density mapping catheter



Endo-vascular

- China **↑31%** YOY (Castor® **↑31%**, Minos® **↑85%**, Reewarm® PTX **↑60%**)
- Non-China revenue **↑75%** YOY, strategically investment to Optimum Medical Device Inc., strengthen European sales & distribution network



Neuro-vascular

- China **↑43%** YOY, **Top 1** domestic player with **8%** market share; Tubridge® & APOLLO™ gained **Top 1** market share of all brands; successful **HKEx** listing
- Non-China revenue **↑3,492%** YOY, sales of NUMEN® ramp up



Surgical robot

- Revenue **↑905%** YOY, completed **1st commercial installation** for **Toumai®**, obtained **multiple bidding orders** for Toumai® & Skywalker®, installation on-track
- Established **40+** training centers & trained **400+** surgeons



Ortho-pedics

- Non-China **↑10%** YOY (EMEA **↑33%**)
- Revenue in China: 2H22 **up 68%** vs. 1H22 (Joint products **↑192%**)



Surgical device

- Completed domestic production of MOBYBOX ECMO®, the **1st fully integrated ECLS** to provide both blood flow and gas management in a single device



R&D achievements

- Firehawk®** clinical trials (for FDA assessment) **completed enrollment**
- Rotational atherectomy catheter** under clinical trail & entered **NMPA Green Path**

- MRI compatible** ICDs/CRT-Ds & leads obtained **CE mark**, incl. **Ulys™ /Edis™** ICD, **Gali™** CRT-D, as well as related **Invicta™** ICD lead

- Self-developed TMVR system (**world's 1st** clinical-phase dry-tissue TMVR system) **launched FIM**, 6 month follow-up shown **great safety & efficacy**

- FireMagic® TrueForce®** contact force-sensing catheter & **EasyStars®** high density mapping catheter obtained **NMPA**

- Talos®** & Reewarm® PTX DCB.35 & Hercules® Φ32 obtained **NMPA**
- Fishhawk™** admitted in **NMPA Green Path**

- Four NMPA** approvals, incl. Neurohawk®, NUMEN Silk®, Diveer®, and X-track®
- Rebridge®** entered **NMPA Green Path**

- SkyWalker™ TKA** obtained **NMPA & FDA & CE**, **THA** submitted for **NMPA**
- R-ONE®** & **Mona Lisa** submitted for **NMPA**

- Five NMPA** approvals, incl. new generation of China-made medial-pivot knee system & VenusOne Eco Bio-acetabular system

- VitaSprings™** obtained **NMPA**, became the **1st** highly integrated China-developed membrane oxygenator

- Beyond Prefer™** guide wire obtained **NMPA**; micro catheter & anchor balloon & guide catheter submitted **NMPA**; scoring balloon & shockwave balloon completed **1st enrollment**

- BonaFire™** passive pacing lead completed registrational clinical trials & **submitted for NMPA** preview

- VitaFlow® III** embedded with the **world's 1st** steerable retrievable delivery system **completed animal study**

- IceMagic®** cryoablation system & catheter submitted for **NMPA**
- Four FDA** approvals obtained in 2022

- Vflower®** completed **last-enrollment**
- Cratos®** & **Aegis II®** & **Vewatch®** & **TIPS** stent graft system launched clinical trials

- Tigertriever®** & **W-track®** submitted for **NMPA** review
- Tigertriever®13** obtained **FDA** clearance

- Toumai®** completed **~700** clinical verification surgeries, deployed **world's longest** distance 5G ultra-remote surgeries


- Hinge knee joint system completed testing for **FDA**, **Procotyl® P Cup** under testing for **FDA** assessment;

- Hemovent WATCHA™** blood oxygen saturation monitoring sensor obtained **CE**
- Femoral cannula** series submitted for **NMPA**



Total-cardio solutions

Global Strategic Triangle



Contents


- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements




Business highlights

Revenue Overview

USD: million



* due to enormous depreciation of RMB against US\$



#1 China
#2 Global
Market share



China




Non-China




R&D

- 2022 revenue \$134.1mn, up 2% YOY, despite the incessant impact of the pandemic
- Guaranteed DES volume doubled in the continued procurement of VBP (v.s. 2020); newly approved Firebird Pro+® win the bid; bid-winning price increased of the renewal contract
- DES products covered 3,200+ hospitals; balloon products covered ~1,500 hospitals; Firehawk newly developed ~200 hospitals
- 2022 revenue \$25.4mn, up 60% YOY (EMEA +143%, South America +59%), market share ramp up in multiple nations & achieved dominant position (incl. Argentina, Brazil, Thailand, etc.)
- Indian JV ↑25% thanks to our **multi-brand strategy**, as well as strong local India commercial & manufacturing capabilities of Firehawk IN™
- Accumulatively launched 40 countries; DES/ balloon received 8/ 6 new approvals, respectively
- Firehawk TARGET IV-NA trial for FDA assessment **completed last enrollment**; Firesorb® released FUTURE-II 3-year follow-up results, completed FUTURE-III 1-year follow-up
- Beyond Prefer™ guide wire obtained NMPA approval; micro catheter & anchor balloon & guide catheter submitted NMPA; shockwave balloon & scoring balloon completed first enrollment
- Coronary rapamycin **DCB** completed all patient enrollment; 1st Chinese-developed coronary rotational atherectomy catheter under clinical trails & entered **NMPA Green Path**

Product pipeline



Non-China business



Business highlights

- 2022 revenue \$202.4mn, **up 10% YOY**, despite components & staffing shortage
- EMEA recorded rapid revenue growth of **33%**, driven by strong double-digit growth in direct subsidiary markets and distributor markets
- Market leading growth in **Knees**, thanks to global recognition of Medial Pivot
- Released **ProFemur® Cemented XM Stem & HIPTURN™ Hip Tensioner**
- Hinge knee joint system** completed testing for FDA (510k); **Procotyl® P Cup** under testing for FDA (510k) assessment




Cost savings

- Cost saving through continuous focusing on expense management
- Kept enhancement of **collaboration between China and the US**, on-going projects incl. plasma spray, Evolution® & Advance® semi-finish
- Multiple steps transferring from vendors to **in-house** manufacturing

Collaboration with Medbot


- Skywalker™ installed in **4** hospitals in the US
- First surgeries utilizing Skywalker™ robotics system with the Evolution™ knee performed in North America (Nov-22)

China business



Joints


- 2022 revenue \$21.1mn, **up 2.9% YOY**; 2H22 **increased by 68%** as compared with 1H22, amid COVID impact in China
- Revenue of China-made joints increased by **208% YOY**, contributes **~33.4%** of the total sales
- Fast growth of distribution channel, **up ~30% YOY**; hospital penetration remains steady growth; rapid enhancement of brand awareness
- Five NMPA** approvals, incl. new generation of China-made medial-pivot knee system & VenusOne Eco Bio-acetabular system & 3D knee planning system
- Strong recovery in 2023**, smooth progressing of cost-saving projects



Spine & Trauma

- 2022 revenue \$4.4mn, down **21.0% YOY**, decrease mainly caused by reduced orders due to VBP policy
- Leveraging the winning of national & provincial VBP tenders, total hospital coverage reached **1,000+**
- Four NMPA** approvals, **five** products to be submitted for NMPA review
- Takin spinal posterior fixation system & arbores balloon dilatation system **successfully commercialized** in Argentina

Non-China business



1 One of the **ONLY 5** multi-national players




* due to enormous depreciation of Euro against US\$




- 2022 revenue \$191.1mn, up 3% YOY, sales in Japan affected by Covid surf
- Substantial sales growth in the Middle East (up 293% YOY), Latin America (up 249% YOY), and Australia (up 35% YOY)
- Soaring sales of Bluetooth® pacemakers (already approved in EU & Japan & Australia & Canada)
- Invicta™ ICD lead (MRI) certified by CE in Jul-22, enabling 1.5T/3T MRI compatible systems for our ICD & CRT-D portfolio, allowing access to the European market with a full range of MRI-compatible defibrillation systems

Product pipeline



Products newly approved for marketing

China business



1 Top 1 Chinese player
No. 1 market share for China-made products




* due to enormous depreciation of RMB against US\$



- 2022 revenue \$13.1mn, up 7% YOY, despite the continued disruption from Covid constrains
- Sales ramp-up of **China-made pacemakers**; leverage on bid-winning in provincial VBPs, hospital penetration reached ~850 (entered ~250)
- **First** China-made MRI compatible pacemaker Rega® obtained NMPA¹ approval and goes into production
- Platinum™ ICD & BeFlex™ pacing lead (MRI) obtained NMPA¹; BonaFire™ passive pacing lead completed clinical trials, submitted for NMPA preview


Product pipeline



Business highlights

Key Financials

USD: million



China



- **2022 revenue \$133.2mn, up 31% YOY**, sales of innovative products boost
- Castor®, the world's **only-in-class** thoracic branch stent-graft system recorded rapid sales growth (+31% YOY), hospital coverage reached **860**
- Minos® sales ramp up in 2022 (+85% YOY), hospital coverage reached **600**
- Reewarm® PTX sales **up 60% YOY**, covered **630** hospitals (250 newly developed), with Reewarm® PTX DCB .35 obtained NMPA, patient pool swells
- Fishhawk™ clinical trail smoothly progressing & admitted in **NMPA Green Path**
- **Four** innovative products launched clinical trials: Cratos® Thoracic Endovascular Stent Graft System & Aegis II® Abdominal Aortic Stent Graft System & Vewatch® Vena Cava Filter & TIPS Stent Graft System



Non-China

- **Overseas revenue increased by 75% YOY**, 5 products obtained **CE mark**, products covered **22** overseas markets across **EU, South America** and **Asia**
- Castor® (custom-made) approved for commercialization in **EU**, Minos® newly approved in **Korea & Columbia**; Reewarm® PTX DCB approved in **Brazil**; Hyperflex® Balloon Catheter approved in **Japan**, Hercules® Low Profile commercialized in **India**, 6 core products successfully approved in **Belarus**
- Leverage on investment to Optimum Medical Device Inc., strengthen European sales team and distribution network


Product pipeline

	Product	Pre-clinical	Clinical	Registration
Aortics Stents	Talos® Thoracic Stent Graft System 		✓ NMPA approved	
	Cratos® Branched Aortics Stent Graft System		• Launched clinical trials	
	Aegis® II Abdominal Aortic Stent Graft System		• Launched clinical trials	
Peripheral Products	Vflower® Iliac Venous Stent System 		• Completed all patient enrollment	
	Fishhawk™ Mechanical Thrombectomy Catheter		• Launched clinical trials • Admitted in NMPA Green Path	
	Vewatch® Vena Cava Filter		• Launched clinical trials	
Oncological	TIPS Stent Graft System		• Launched clinical trials	



MicroPort
微创脑科学
2172.HK

- Successfully listed on HKEx on July 15, 2022
- Becoming the **4th** subsidiary to accomplish public listing



China

- 2022 revenue \$79.9mn, up 43% YOY**, thanks to sales burst of new products
- Newly penetrated **~500** hospitals, total coverage reached **~2,600**; actively developed primary market, **Eagle & Swallows** program covered **~600** hospitals in lower-tier cities and counties, kept enhancing penetration
- Tubridge® achieved rapid growth, gained **Top 1** market share in China (**> 45%**); NUMEN® won tenders in provincial VBPs, volume doubled (market share **> 5%**)
- APOLLO™ maintained **Top 1** market share, Bridge® sales rump up (**+~400%**)
- Sales increment contribute by commercialization of **Neurohawk®** & **X-track™**
- Rebridge®**, coil embolization assisting stent entered NMPA Green Path



Non-China

- International business generated revenue of \$3.2mn (up 3,492% YOY)**
- NUMEN® entered **7** countries/ regions, completed multiple commercial implantations overseas; APOLLO™ successfully commercialized in **Brazil**
- NUMEN® sales ramp up in Korea, thanks to inclusion in medical insurance catalogue in 2022; fast business-promotion in the US leverage on sales network and complementary product portfolio of Rapid Medical (associated company)
- Established subsidiaries in the **US, UK, Netherland**, and **Brazil**; set up regional marketing headquarters in **EMEA, North America**, and **Asia**




Note: 1. revenue growth rate adjusted to exclude foreign exchange impact, due to appreciation or depreciation of US\$ against functional currencies

	Product	Pre-clinical	Clinical	Registration
Hemorrhagic Stroke	NUMEN Silk™ 3D Electronically Detachable Coil	✓ NMPA approved		
	Comaneci® Embolization Assist Device*	• CE marked & FDA cleared • FDA Breakthrough Device Designation		
	Rebridge® Intracranial Visualized Stent	• Admitted in NMPA Green Path		
Cerebral Atherosclerotic Stenosis	Diveer™ Intracranial Balloon Dilatation Catheter	✓ NMPA approved		
	Intracranial Drug-Coated Balloon Catheter System	• Design development		
Acute Ischemic Stroke	Neurohawk® Stent Thrombectomy Device	✓ NMPA approved		
	Tigertriever® Revascularization Device*	• CE marked & FDA cleared • Submitted for NMPA review		
	Tigertriever® 13 Revascularization Device*	✓ FDA cleared • World's smallest clot retriever		
	X-track™ Intracranial Distal Access Catheter	✓ NMPA approved		
	W-track® Intracranial Aspiration Catheter	• Clinical trial waived • Submitted for NMPA review		
	Balloon Guide Catheter	• Clinical trial waived • Submitted for NMPA review		

Product admitted to NMPA Green Path * Products we act as exclusive distributor for Rapid Medical

Business highlights



China

- Revenue up 25% YOY, implantations up ~31% YOY (2,562 procedures), outperforming China market by 14 ppt²
- GPM up 6 ppts, benefited from continuous effective cost-cut measures
- Newly developed 130+ hospitals, total coverage reached ~440
- Ramp up patient discovery and referral mechanism and continue to incubate TAVI centers and physicians



Non-China

- Rapid overseas revenue growth, up 626% YOY
- Gaining market share in Argentina & Colombia
- Covered ~40 hospitals overseas, conducted ~100 commercial implantations
- VitaFlow Liberty™ & Alwide® Plus approved in Colombia & Thailand
- VitaFlow Liberty™ made continued CE marking progress under MDR regulations



R&D progress

- VitaFlow® III embedded with the world's 1st steerable retrievable delivery system completed animal study, approaching design freeze stage
- Self-developed TMVR system launched FIM, became world's 1st clinical-phase dry-tissue TMVR system, 6-month follow-up confirmed safety & efficacy
- Alwide® balloon catheter III NMPA registration in progress

Product pipeline

	Product	Pre-clinical	Clinical	Registration
TAVI (aortic valve)	VitaFlow Liberty™	• CE marking in progress		
	VitaFlow™ III	• Approaching design freeze		
	VitaFlow™ Novo Generation	• Design stage		
	VitaFlow™ Balloon Expandable	• Animal studies		
Procedural Accessories	Alwide® balloon catheter III	• NMPA approval in progress		
	Expandable Sheath	• Design stage		
	Self-developed replacement product	• FIM studies		
TMV (mitral valve)	AltaValve™ - replacement product	• Early feasible studies		
	Helios™ - replacement product	• Animal studies		
	Self-developed edge to edge repair product	• Design stage		
	Amend™ - repair product	• Early feasible studies		
TTV (tricuspid valve)	Self-developed edge to edge repair product	• Design stage		
	Trivid™ - repair product	• Animal studies		
	Replacement product - partnership with 4C	• Design stage		
Surgical	Aortic valve replacement product	• Design stage		
	Mitral valve replacement product	• Design freeze		

Business highlights



- 2022 revenue \$3.1mn, **up 904.8% YOY**, thanks to the 1st **commercial installation** of Toumai®, as well as rapid sales ramp-up of DFVision®
- Toumai® & SkyWalker™ obtained multiple bidding orders, installation on track; Mona Lisa deployed first commercialization sales in Taiwan
- Self-owned and co-developed **40+** training centers, trained **400+** surgeons;
- Completed **over 1,000** robot-assisted clinical verification surgeries in total, incl. a large proportion of complicated cases first time conducted in China



Laparoscopic surgery

- Toumai® 1st Generation obtained **NMPA**
- Toumai® 2nd Generation completed registrational clinical trial in gynecologic, thoracic & general surgeries
- Toumai® completed **world's longest-distance 5G** ultra-remote surgeries, in urology & hepatobiliary, respectively
- Toumai® single-arm started enrollment of registrational trial

Orthopedic surgery

- SkyWalker™ (TKA) obtained **NMPA & FDA & CE**
- SkyWalker™ (THA) completed **FIM** surgery
- SkyWalker™ completed the 1st Unicompartmental knee arthroplasty

Natural orifice surgery

- Trans-bronchial Surgical Robot kick off enrollment in near term

Panvascular surgery & Percutaneous surgery

- **R-ONE® & Mona Lisa** both completed registrational clinical trial and submitted for **NMPA**



- SkyWalker™ became the 1st and **only** Chinese-developed surgical robot to obtain **FDA (510k) clearance & CE mark**
- SkyWalker™ installed in **4 hospitals** in the US, completed 1st clinical use of total knee replacement procedure in Nov, 2022
- R&D centers established in multiple overseas countries, incl. Singapore and the US

	Product	Pre-clinical	Clinical	Registration
Laparoscopic	Toumai® Laparoscopic Surgical Robot ("Toumai®")	✓ Obtained NMPA		
	Toumai® 2 nd Generation		• Submitted for NMPA review	
	Toumai® Single-arm Laparoscopic Surgical Robot		• Started enrollment of registrational trial	
Orthopedic	Skywalker™ Orthopedic Surgical Robot	✓ Obtained NMPA approval ✓ Obtained FDA & CE approval		
	Spine Surgical Robot		• Design validation stage	
Natural Orifice	Trans-bronchial Surgical Robot		• Kick off enrollment in near term	
Panvascular	R-ONE® Vascular Interventional Surgical Robot		• Submitted for NMPA review • Obtained CE in 2019	
	TAVR Surgical Robot		• Design development stage	
Percutaneous	iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System ("Mona Lisa™")		• Submitted for NMPA review • Obtained CE & FDA in 2017	
	Thoracic and Abdominal Puncture Robot		• Design validation stage	



Business overview

- Provider of **complete and systematic life support solutions for acute critical cases**, product portfolio includes ECMO system, oxygenator, etc.
- 2022 revenue \$4.5mn**, strongly affected by the pandemic
- 1st highly integrated** China-developed membrane oxygenator, Vitasprings™, obtained NMPA approval, and completed commercial use



Product overview

18

Products received
NMPA approvals

9

Products received
CE mark

Flagship – MOBYBOX ECMO System

- 1st fully integrated ECLS system** to provide both blood flow and gas management in a single device
- Study confirms its safety and efficacy in treating ARDS
- Received 2022 German Design Award of Medical Device











Globalization

10

Overseas markets
received product
approvals

16

Countries with
established sales
channels

	Product	Pre-clinical	Clinical	Registration
Emergency transport system	Hemovent ¹ MOBYBOX® ECMO 	✓ Obtained CE mark		
	Hemovent ¹ MOBYO™ ECMO Oxygenator	✓ Obtained CE mark		
	Hemovent ¹ WATCHA™ blood oxygen saturation monitoring sensor	✓ Obtained CE mark		
ECMO	Centrifugal ECMO system			
	Double lumen cannula			
	Transseptal cannula			
CPB	Vitasprings™ membrane oxygenator	✓ Obtained NMPA approval		
	Cannula series	✓ Obtained NMPA approval & CE mark		
	Femoral cannula series	✓ Submitted NMPA application		
Congenital heart diseases	Atrial septal defect occluder 	✓ Obtained NMPA approval		
	Patent ductus arteriosus occluder 	✓ Obtained NMPA approval		
	Ventricular septal defect occluder 	✓ Obtained NMPA approval		
	Occluder delivery system	✓ Obtained NMPA approval		
	Patent foramen ovale occluder			
Others	Patient monitoring system			
	Data processing platform			
	ICU management			
	Heart failure			
	In-hospital transport system			

 Product admitted in NMPA Green Path



Business highlight

- Provide **total precise interventional imaging solution**, multifaceted coverage including panvascular (cardiovascular, neurovascular, and peripheral vascular), structural heart/EP, metabolism and etc.
- **2022 revenue \$3.0mn**, thanks to successful marketing of the **1st** fully sealed purge-free catheter Argus NOPURGE™ (disposable OCT catheter)
- Soul-Man™ DSA System successfully signed contract with **3** hospitals
- Self-developed IVUS imaging system & accompanying disposable catheter commenced type examination



Flagship products

ArgusClarity™ OCT system & NOPURGE™ catheter



Decreases the amount of contrast agent used



Reduces the operation steps and time

Soul-Man™ DSA System



Low dose acquisitions



Compact design



Intelligent human-machine interactions



High resolution images

	Product	Indication	Pre-clinical	Clinical	Registration
OCT	Insight-100 ArgusClarity™	PCI	✓ Obtained NMPA approval		
	Insight-100-1350 NOPURGE™ (OCT catheter)	PCI	✓ Obtained NMPA approval		
	Insight-100h High Speed OCT	PCI	✓ Obtained NMPA approval		
	High Resolution OCT	PCI	• Clinical trial waived		
DSA	Peripheral/Intracranial OCT	Panvascular			
	Soul-Man™ DSA System	Interventional	✓ Obtained NMPA approval		
IVUS	Coronary Artery IVUS	PCI	✓ Submitted for type examination		
	Peripheral/Intracranial IVUS	Panvascular			
	IVUS-ICE	SHD			
Multi-module interventional	OCT+IVUS	PCI	✓ Prototype development stage		
	OCT+IVUS+FFR	PCI			
MRI	Imported MRI System	Prostate biopsy	✓ Obtained FDA approval		
	Chinese MRI System	Prostate biopsy			



Business highlights

- Provide innovative total solutions in endoscope and disposal devices to **urological, gastrointestinal, gynecological & respiratory** diseases, **18 NMPA** certificates in total
- Two** single-use digital endoscope, flexible ureteroscope catheter & choledochoscope catheter approved by **NMPA**
- Ruyi Clip™ approved by **NMPA**, world's 1st hemostatic clip for large wound closure used in the GI tract



R&D progress

30+
Product candidates
in pipeline

1
Products obtained
NMPA Green Path

Key product – 1st in China, 2nd globally

- Prostatic urethral lift system admitted in **NMPA Green Path** and completed FIM, began patient enrollment for registration clinical trial




Globalization

5
Products received
overseas registration
approvals

3
Products submitted
registration application
for CE mark

	Product	Indication	Pre-clinical	Clinical	Registration
Single-use endoscope	Single-use digital ureteroscope catheter	Urology	✓	Obtained NMPA approval	
	Single-use digital choledochoscope catheter	Gastroenterology	✓	Obtained NMPA approval	
	7 other candidates covering urological, gastrointestinal, gynecological and respiratory indications				
Reusable endoscope	3 candidates covering gastrointestinal and respiratory indications				
Passive consumables	Nephrostomy balloon dilation catheter		✓	Obtained NMPA approval	
	Single-use endoscopic retrieval basket (3 claws)		✓	Obtained NMPA approval	
	Ureteral access sheath		✓	Obtained NMPA approval	
	Single-use urinary track guidewire	Urology	✓	Obtained NMPA approval	
	Ureter balloon dilation catheter		✓	Obtained NMPA approval	
	Prostatic urethral lift system		✓	Launched registration trial	
	Hybrid zebra guidewire				
	Ultrathin basket				
	Ruyi Clip™ soft tissue clip	Gastroenterology	✓	Obtained NMPA approval	
	6 other candidates covering gastrointestinal and urological indications				
Energy-based	5 candidates covering general, gynecological and gastrointestinal indications				
Neuro modulation	3 candidates covering urological and respiratory indications				

Product admitted in NMPA Green Path



Contents

1

Company Highlights

2

Business Review

3

Financial Review

4

Outlook


5

Appendix – Financial Statements



Revenue

USD: million




Gross profit margin




Operating expenses

USD: million




Total net loss & net loss attributable to equity shareholders

USD: million



Sales & marketing expenses

USD: million




Sales & marketing expenses increased by 10.3%^{YOY}

- ◆ Increase in marketing activities and product promotion

Administrative expenses

USD: million




Administrative expenses decreased by 1.0%^{YOY}

- ◆ Due to the Group's effective cost control and scale of operations.

R&D expenses

USD: million



R&D expenses increased by 41.0%^{YOY}

- ◆ Due to increased investments in R&D projects

Contents

1

Company Highlights

2

Business Review

3

Financial Review

4
























Outlook

5

Appendix – Financial Statements



Innovative product pipeline fueling long-term growth

Cardio-vascular	Micro-catheter NMPA	Anchor Balloon NMPA	Firesorb® Bioresorbable Scaffolds NMPA&CE 	Coronary Rotational Atherectomy System NMPA&CE 	Scoring Balloon NMPA	Coronary Rapamycin DCB NMPA	Firehawk® FDA	Coronary Stent Graft System NMPA	Intravascular Lithotripsy Balloon NMPA&CE 
Orthopedics	Classic Profemur® Cemented XM® Femoral Stem FDA		Zirconium Niobium Alloy Femoral Head NMPA	Hinged Knee Joint System FDA 		Evolution Tibia Cones FDA 	2D-to-3D Imaging Technology FDA 	Wrist Joint Prosthesis System NMPA	
CRM	Bluetooth® ICD & CRT-D CE 		ENO™ Pacemaker & BonaFire™ Passive Lead (MRI) NMPA 	Space HP ICD/CRT-D NMPA 		Invicta™ ICD Lead & Navigo™ CRT Lead (MRI) NMPA 	LBB pacing lead CE 	Leadless Pacemaker NMPA&CE 	
Endo-vascular	Vflower® Iliac Venous Stent System NMPA 		Fishhawk™ Mechanical Thrombectomy Catheter NMPA	Vena Cava Filter NMPA		Cratos Branched Aortics Stent Graft System NMPA		Aegis® II Abdominal Aortic Stent Graft System NMPA	TIPS Stent Graft System NMPA
Neuro-vascular	Tigertriever™ Revasculari- zation Device NMPA 		X-track™ Intracranial Distal Access Catheter NMPA	Comaneci® Embolization Assist Device NMPA		Rebridge® Intracranial Visualized Stent NMPA		Tubridge Plus™ Flow- diverting Stent NMPA	Balloon Protection Guiding Catheter NMPA
Heart Valve	VitaFlow® III NMPA	VitaFlow™ Novo Generation NMPA	VitaFlow® Balloon Expandable NMPA	Mitral Replacement: Self-developed replacement product		Mitral Replacement: AltaValve™ Helios™ 	Mitral Repair: Self-developed edge to edge repair product Amend™ 	Tricuspid Repair: Self-developed edge to edge repair product Trivid	
Surgical Robot	Toumai® 2nd Gen Laparoscopic Surgical Robot NMPA 		R-ONE® Panvascular Surgical Robot NMPA 	iSR'obot™ Mona Lisa Robotic Transperineal Prostate Biopsy System NMPA 		Toumai® Single-arm Laparoscopic Surgical Robot	Trans- bronchial Surgical Robot NMPA	TAVR Surgical Robot NMPA	Spine Surgical Robot NMPA
Surgical Devices	Femoral Arterial & Venous Cannula NMPA		Arterial Micro-Embolic Filter (new type) NMPA	MOBYBOX System NMPA 		Centrifugal ECMO system NMPA 	Double lumen cannula NMPA	Transseptal cannula NMPA	
Electro- physiology¹	Columbus™ 3D EP Navigation System V4 NMPA		IceMagic® Cardiac Cryoablation System NMPA 		Cryoablation Catheter NMPA 		Renal RF Ablation System NMPA	Flashpoint® Renal Artery Ablation Catheter NMPA	

Contents

- 1 Company Highlights
- 2 Business Review
- 3 Financial Review
- 4 Outlook
- 5 Appendix – Financial Statements



USD'000	2022	2021	Var.
Revenue	840,831	778,639	8.0%
Cost of sales	(339,060)	(286,866)	18.2%
Gross profit	501,771	491,773	2.0%
Other net income	36,150	76,475	-52.7%
Research and development costs	(419,828)	(297,778)	41.0%
Distribution cost	(328,232)	(297,532)	10.3%
Administrative expenses	(247,532)	(250,010)	-1.0%
Other operating costs	(49,279)	(16,547)	197.8%
Loss from operations	(506,950)	(293,619)	72.7%
Finance cost	(78,401)	(47,883)	63.7%
Gain on deemed disposal of a subsidiary	7,107	8,218	-13.5%
Gain on deemed disposal of interest in equity-accounted investees	39,267	9,215	326.1%
Share of losses of equity-accounted investees	(42,541)	(13,255)	220.9%
Loss before taxation	(581,518)	(337,324)	72.4%
Income tax	(6,597)	(13,971)	-52.8%
Loss for the period	(588,115)	(351,295)	67.4%
Attributable to: Equity shareholders of the Company	(436,515)	(276,484)	57.9%

USD'000	31 Dec 2022	31 Dec 2021	Var.
Non-current assets			
Investment properties	6,579	7,407	-11%
Other property, plant and equipment	993,014	922,874	8%
Intangible assets	223,683	256,609	-13%
Goodwill	262,829	290,565	-10%
Equity-accounted investees	423,873	363,103	17%
Other financial assets	23,155	30,184	-23%
Deferred tax assets	27,637	20,368	36%
Other non-current assets	94,081	102,652	-8%
Total non-current assets	2,054,851	1,993,762	3%
Current assets			
Inventories	352,428	289,931	22%
Trade and other receivables	284,833	308,126	-8%
Pledged deposits and time deposits	60,765	32,890	85%
Cash and cash equivalents	1,203,007	1,754,414	-31%
Derivative financial assets	38,201	1,406	2617%
Total current assets	1,939,234	2,386,767	-19%
Current liabilities			
Trade and other payables	380,554	358,792	6%
Contract liabilities	22,598	23,590	-4%
Lease liabilities	51,944	50,505	3%
Interest-bearing borrowings	185,387	94,746	96%
Income tax payable	17,470	19,124	-9%
Derivative financial liabilities	4,172	-	N/A
Total current liabilities	662,125	546,757	21%
Net current assets	1,277,109	1,840,010	-31%

Interest-bearing borrowings	336,689	269,637	25%
Lease liabilities	124,373	168,437	-26%
Deferred income	38,123	35,098	9%
Convertible bonds	769,553	660,369	17%
Contract liabilities	24,839	26,243	-5%
Other payables	220,997	425,914	-48%
Deferred tax liabilities	24,718	27,692	-11%
Derivative financial liabilities	-	2,890	-100%
Total non-current liabilities	1,539,292	1,616,280	-5%
CAPITAL AND RESERVE			
Share capital	18	18	-
Reserves	1,135,012	1,490,732	-24%
Total equity attributable to equity shareholders of the Company	1,135,030	1,490,750	-24%
Non-controlling interests	657,638	726,742	-10%
Total equity	1,792,668	2,217,492	-19%

This document is for information purposes only and does not constitute or form part of any offer or invitation to sell or the solicitation of an offer or invitation to purchase or subscribe for any securities of MicroPort Scientific Corporation, and no part of it shall form the basis of, or be relied upon in connection with, any agreement, arrangement, contract, commitment or investment decision in relation thereto whatsoever.

FORWARD-LOOKING STATEMENTS

Some information contained in this presentation contains forward-looking statements. These forward-looking statements include, without limitation, those regarding our future financial position, our strategy, plans, objectives, goals and targets, future developments in the markets where we participate or are seeking to participate, and any statements preceded by, followed by or that include the words “believe”, “intend”, “expect”, “anticipate”, “project”, “estimate”, “predict”, “is confident”, “has confidence” and similar expressions are also intended to identify forward-looking statements. Such statements are based upon the current beliefs and expectations of MicroPort’s management and are subject to significant risks and uncertainties. MicroPort Scientific Corporation undertakes no obligation to update any of the statements. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and other factors that could cause actual future results to differ materially from current expectations include, but are not limited to, general industry and economic conditions, PRC governmental policies and regulations relating to the medical device manufacturing industry, competition in the medical device manufacturing industry, our ability to develop new products and stay abreast of market trends and technological advances, our goals and strategies, our ability to execute strategic acquisitions of, investments in or alliances with other companies and businesses, fluctuations in general economic and business conditions in China and other countries that MicroPort operates in.

CONFIDENTIALITY

This presentation is confidential and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, in whole or in part, for any purpose.